Novel highly flexible collagen-loaded latex dressing to treat diabetic foot ulcer: A pilot clinical trial
Diabetic Foot Ulcers (DFUs) are a common and severe complication of long-term, poorly managed type 2 diabetes. Among the 537 million people worldwide with type 2 diabetes, 19 % to 34 % are expected to develop a DFU in their lifetime. As life expectancy increases, so does the prevalence of DFUs, lead...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | Brasil |
| Institución: | Universidade Estadual Paulista (UNESP) |
| Repositorio: | Repositório Institucional da UNESP |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.unesp.br:11449/300287 |
| Acceso en línea: | http://dx.doi.org/10.1016/j.ijbiomac.2025.142615 https://hdl.handle.net/11449/300287 |
| Access Level: | acceso abierto |
| Palabra clave: | Collagen Diabetic foot ulcers Natural rubber latex Pilot clinical study Regenerative medicine Wound healing |
| Sumario: | Diabetic Foot Ulcers (DFUs) are a common and severe complication of long-term, poorly managed type 2 diabetes. Among the 537 million people worldwide with type 2 diabetes, 19 % to 34 % are expected to develop a DFU in their lifetime. As life expectancy increases, so does the prevalence of DFUs, leading to complex and costly long-term care. This study introduces a novel, flexible dressing composed of natural rubber latex (NRL) infused with collagen (NRL-C), leveraging the natural healing properties of these biomaterials. The efficacy of NRL-C was validated through physicochemical characterization, in vitro and in vivo studies, and a pilot clinical trial. Results demonstrated that the NRL-C dressing promotes angiogenesis in endothelial cells, stimulates fibroblast and keratinocyte proliferation, accelerates wound closure, and exhibits biocompatibility in rodent models. Additionally, a pilot clinical study involving six diabetic patients revealed promising therapeutic outcomes, highlighting the potential of NRL-C as a cost-effective, safe, and sustainable strategy for DFU treatment. |
|---|